Description
This workshop will examine the impact of mental health and treatment on lung function decline and risk of future exacerbations. In addition, the interpretations of conditional survival and reproducibility of FEV1 will be described.
Learning Objectives:
- Describe the impact of depression, mucolytics, and antibiotics on lung function decline in the US and Europe.
- Identify a clinically meaningful change in FEV1 for CF patients.
- Review the interpretation of conditional survival and the factors that are associated with an increased risk of death before age 30.
Workshop Chair(s):
Speaker(s):
Workshop Chair(s):
Workshop Speaker(s):
- Edward
McKone,
M.D.,
Consultant Physician
- Michelle
Murray,
M.D., M.Sc., MRCPI,
Doctor
- Michael
Schechter,
M.D., M.P.H.,
Director
- Sanja
Stanojevic,
Ph.D.,
Senior Research Associate